Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific sales buoyed by 219% Taxus growth:

This article was originally published in Clinica

Executive Summary

Boston Scientific's sales rose by 49% to $1.6bn in the first quarter, as its Taxus drug-eluting stent generated growth of 219% to $686m. Sales of the device were $494m in the US, where it was launched in March 2004. The company's net income rose by 85% to $358m. "In the coming quarters, we expect our recent dramatic growth to return to more moderate levels, following a full year of Taxus system sales in the US", said president and CEO Jim Tobin. The company holds some 60% or more of the US DES market, with Johnson & Johnson its only commercial competitor to date (see page 13).

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel